SCHEMBL7140434

SCHEMBL7140434

O=C(O)CC(NS(=O)(=O)c1cccc([N+](=O)[O-])c1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 4/20 0.69
L3MBTL1 Q9Y468 3/20 0.58
ALDH1A1 P00352 2/20 0.58
ATM Q13315 2/20 0.58
CA2 P00918 2/20 0.56
MMP2 P08253 2/20 0.56
CA12 O43570 1/20 0.56
CA9 Q16790 1/20 0.56
ITGB3 P05106 4/20 0.55
ITGAV P06756 4/20 0.55
KMT2A Q03164 2/20 0.54
CA1 P00915 1/20 0.54
MMP1 P03956 1/20 0.54
MMP9 P14780 1/20 0.54
MMP8 P22894 1/20 0.54
MMP13 P45452 1/20 0.54
MAPT P10636 1/20 0.54
MEN1 O00255 1/20 0.53
DDX3X O00571 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7315916 1.00 EEF2K (0.69) EEF2KL3MBTL1ALDH1A1ATMCA2
SCHEMBL13418142 0.88 EEF2K (0.61) EEF2KL3MBTL1ALDH1A1ATMCA2
SCHEMBL7146586 0.86 ALDH1A1 (0.73) EEF2KL3MBTL1ALDH1A1ATMCA2
SCHEMBL28404274 0.82 ATM (0.76) EEF2KL3MBTL1ALDH1A1ATMITGB3
SCHEMBL28405808 0.82 EEF2K (1.00) EEF2KL3MBTL1CA2MMP2CA12
SCHEMBL6772863 0.81 EEF2K (0.66) EEF2KL3MBTL1ALDH1A1ATMITGB3
SCHEMBL7144205 0.80 EEF2K (0.64) EEF2KL3MBTL1ALDH1A1ATMITGB3
SCHEMBL3839370 0.79 ALDH1A1 (0.76) EEF2KL3MBTL1ALDH1A1ATMCA2
SCHEMBL3310158 0.79 EEF2K (0.66) EEF2KL3MBTL1ALDH1A1ATMITGB3
SCHEMBL644240 0.79 EEF2K (0.66) EEF2KL3MBTL1ALDH1A1ATMITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107903185-B Preparation and application of novel eEF2K inhibitor 四川大学 2020-05-26 CN disclosed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 EEF2K 1935/4885L3MBTL1 1072/4885ALDH1A1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.